New Oral Weight-Loss Drug to Launch in Israel Next Month
Translated & summarized from Kipa by baba
A new daily weight-loss pill, POUNDAIO, will be available in Israel starting September 15, offering an oral alternative to injections. The drug, which requires no fasting or refrigeration, comes with a range of prices and potential side effects.
The story in 5 lines · by baba
- New oral weight-loss drug POUNDAIO launches in Israel September 15.
- It is an alternative to injectable obesity treatments.
- The drug requires daily intake without fasting or refrigeration.
- Prices range from 691.59 to 1,146.46 shekels, initially unsubsidized.
- Common side effects include nausea, vomiting, and diarrhea.
A new oral medication for weight loss, POUNDAIO (orforglipron), is set to become available in Israeli pharmacies on September 15. This daily pill offers an alternative to injectable treatments and is intended for adults with obesity or overweight individuals suffering from weight-related health conditions. Israel will be the fourth country globally to offer the drug commercially, following the United States, the United Kingdom, and the United Arab Emirates.
POUNDAIO is administered once daily without the need for fasting, meal timing, or refrigeration, making it a convenient option for integration into daily routines. Dr. Raz Hagouel, director of the medical center for obesity treatment, highlighted the significance of an oral option for patients who prefer not to use injections, noting its ease of use without special dietary or timing restrictions.
Clinical trials for POUNDAIO demonstrated an average weight loss of 12.4% of body weight at the highest dosage. However, this is lower than the weight loss achieved by some injectable treatments. In Israel, the drug will be available in six dosages, with prices ranging from approximately 691.59 to 1,146.46 shekels, and will not be subsidized initially.
Common side effects reported include nausea, vomiting, and diarrhea. Approximately 10.6% of patients in higher dosages discontinued treatment due to these side effects. Dr. Hagouel emphasized that the expansion of treatment options allows for better personalization, aiming for both efficacy and long-term patient adherence by matching treatments to individual needs and preferences.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 7Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.